Tuesday, March 20, 2018 10:57:34 AM
ROCKVILLE, Md., March 20, 2018 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces today a $50 million private placement. The Company has entered into definitive securities purchase agreements pursuant to which the Company will issue 15,432,091 shares of its Common Stock with accompanying warrants to purchase 6,172,832 shares of its Common Stock. The purchase price for each share of Common Stock and warrant is $3.24. The warrants will become exercisable 180 days after issuance at a $3.69 per share exercise price, and will expire five years from the date of issuance. On March 19, 2018, the consolidated closing bid price per share of Common Stock was $3.19.
The financing was led by ETP Global Fund LP, IDG-Accel China Growth Fund III, and Robert W. Duggan, former Chairman and CEO of Pharmacyclics Inc. The financing is expected to close on or about March 21, 2018. Proceeds will be used by the Company to prepare for the anticipated launch of its first commercial product in China and also for working capital general corporate purposes.
The offering of shares of Common Stock and warrants has not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and the shares are being offered pursuant to an exemption from registration and in reliance on similar exemptions under applicable state laws. The investors will receive certain registration rights in connection with the offering.
Wei-Wu He, Ph.D., CASI’s Executive Chairman commented, “We are grateful that seasoned investors such as IDG and Mr. Duggan share our vision for CASI and our excitement as we prepare for the launch of our first commercial product in China. Our in-licensed products, EVOMELA®, MARQIBO® and ZEVALIN® are currently in various regulatory stages for market approval in China, with EVOMELA® under priority review. We also are working on our portfolio of 29 abbreviated new drug applications (ANDAs) (including 25 FDA-approved and 4 pending approval) that we recently acquired from Sandoz, and will continue to further expand our pipeline as part of our mission to bring innovative and high-quality medicines to the market.”
Recent CASI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 11:30:34 AM
- CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE • PR Newswire (US) • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:05 AM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 08/29/2024 12:00:51 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/16/2024 09:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 12:30:21 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 10:18:15 AM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 07/19/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/19/2024 10:07:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/08/2024 11:48:21 AM
- CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP • PR Newswire (US) • 07/08/2024 11:30:00 AM
- CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company • PR Newswire (US) • 06/26/2024 08:15:00 PM
- CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He • PR Newswire (US) • 06/26/2024 08:10:00 PM
- CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) • PR Newswire (US) • 05/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 10:50:28 AM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 05/14/2024 12:00:00 PM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM